NICE finally makes RoActemra a first-line RA choice in the UK
This article was originally published in Scrip
Executive Summary
New final guidance from NICE, the health technology appraisal body for England and Wales, has made Roche/Chugai's RoActemra (tocilizumab) available earlier in the treatment pathway for patients in England and Wales who have failed on disease modifying anti-rheumatic drugs. However, it is unclear at what stage patients will receive the treatment.